FemasysFEMY +10.14%55 Days Inventory is 3,398.92 as of Mar. 2026, which is 1113% above its 10-year median of 280.27. GuruFocus rates FEMY with a GF Score™ of 55/100 and a GF Value™ of $12.19 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 786 Medical Devices & Instruments companies, Femasys ranks worse than 99.24% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Femasys's Average Total Inventories for the
three
months ended in Mar. 2026 was $5.92 Mil. Femasys's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $0.16 Mil.
Hence, Femasys's Days Inventory for the
three
months ended in Mar. 2026 was 3,398.92.
The historical rank and industry rank for Femasys's Days Inventory or its related term are showing as below:
FEMY'
s Days Inventory Range Over the Past 10 Years
Min: 166.76 Med: 280.27 Max: 2136.75
Current: 2136.75
During the past 7 years, Femasys's highest Days Inventory was 2136.75. The lowest was 166.76. And the median was 280.27.
FEMY's Days Inventory is ranked worse than 99.24% of 786
companies
in the Medical Devices & Instruments industry
Industry Median: 179.6
vs FEMY: 2136.75
Femasys's Days Inventory
increased
from Mar. 2025 (2,693.82) to Mar. 2026 (3,398.92).
It might indicate that Femasys's sales slowed down.
Warning Sign:
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Femasys's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.03.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Femasys's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 13.94.
Femasys (NAS:FEMY) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Femasys's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Femasys's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Femasys Days Inventory Related Terms
Femasys Days Inventory Historical Data
* Premium members only.
The historical data trend for Femasys's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FEMY vs UEEC, BNGO, CUPR: Days Inventory Comparison
For the Medical Instruments & Supplies subindustry, Femasys's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Femasys Days Inventory vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Femasys's Days Inventory distribution charts can be found below:
* The bar in red indicates where Femasys's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Femasys (FEMY) has a Days Inventory of 3,398.92 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Femasys and its competitors. This is 1113% above median its historical median of 280.27. Over the past decade, Femasys' Days Inventory has ranged from 166.76 to 2,136.75. According to the industry distribution chart, Femasys ranks #780 out of 786 companies in the Medical Devices & Instruments industry, placing it in the top 99.2%.
Is Femasys' Days Inventory too high?
Femasys' current Days Inventory of 3,398.92 is 1113% above median its 10-year median of 280.27. Over the past 10 years, this metric has ranged from a low of 166.76 to a high of 2,136.75. The Medical Devices & Instruments industry median Days Inventory is 179.60. Femasys' value of 3,398.92 is 1792.5% above this industry median. Based on the distribution chart, Femasys ranks #780 out of 786 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Femasys has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Femasys' Days Inventory compare to UEEC and BNGO?
According to the Medical Devices & Instruments industry distribution chart, Femasys ranks #780 out of 786 companies for Days Inventory. This places Femasys in the lower half of its industry. The industry median Days Inventory is 179.60. Femasys' value of 3,398.92 is 1792.5% above this benchmark. Historically, Femasys' own Days Inventory has ranged from 166.76 to 2,136.75 over the past decade. While the company's 10-year median is 280.27 vs. the industry median of 179.60, Femasys has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Devices & Instruments company?
The median Days Inventory among Medical Devices & Instruments companies is 179.60, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Femasys's current Days Inventory of 3,398.92 is 1792.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Femasys and its competitors. For the Medical Devices & Instruments industry, the median Days Inventory is 179.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Femasys's current Days Inventory is 3,398.92, which is 1113% above median its own 10-year median of 280.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Femasys stock overvalued right now?
Based on GuruFocus' analysis, Femasys (FEMY) is currently considered Possible Value Trap. The stock's GF Value™ is $12.19, compared to a current price of $4.17 — trading 65.8% below its estimated fair value. The current Days Inventory is 3,398.92, which is 1113% above median its 10-year median of 280.27 and 1792.5% above the Medical Devices & Instruments industry median of 179.60. Femasys' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Femasys (FEMY), the current Days Inventory is 3,398.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Femasys (FEMY) Overvalued in 2026?
Based on GuruFocus' analysis, Femasys stock appears to be undervalued.
The current stock price of $4.17 is trading 65.8% below its estimated GF Value™ of $12.19.
GuruFocus considers Femasys to be Possible Value Trap.
Key valuation signals for FEMY:
Days Inventory: 3,398.92 (1113% above median its 10-year median of 280.27)
GF Value™: $12.19 vs. price of $4.17 (65.8% below fair value)
Industry Position: 1792.5% above the Medical Devices & Instruments median (#780 of 786)
No single metric tells the full story. See the FEMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
55GF Score
Get the complete analysis for FEMY
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FEMY has been successfully added to your 
